(Q33717062)

28 July 2017

1 reference

title

Risk-benefit assessment of therapies for Mycobacterium avium complex infections (English)

1 reference

Mycobacterium avium avium

28 July 2017

main subject

1 reference

D E Griffith

1

1 reference

28 July 2017

publication date

1 August 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

21

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

137-152

1 reference

A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group

28 July 2017

cites work

1 reference

12 December 2020

Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection

1 reference

12 December 2020

Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network

1 reference

12 December 2020

The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study.

1 reference

12 December 2020

The new macrolides. Azithromycin and clarithromycin.

1 reference

12 December 2020

Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis

1 reference

12 December 2020

Treatment of Disease Due to Mycobacterium intracellulare

1 reference

12 December 2020

Intracellular accumulation of azithromycin by cultured human fibroblasts

1 reference

12 December 2020

Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients

1 reference

12 December 2020

Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex

1 reference

12 December 2020

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

1 reference

12 December 2020

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

1 reference

12 December 2020

Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.

1 reference

12 December 2020

Uveitis associated with rifabutin prophylaxis

1 reference

12 December 2020

In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin

1 reference

12 December 2020

Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease

1 reference

12 December 2020

Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus

1 reference

12 December 2020

Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS.

1 reference

12 December 2020

Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases

1 reference

12 December 2020

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease

1 reference

12 December 2020

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

12 December 2020

Pulmonary disease due to Mycobacterium intracellulare.

1 reference

12 December 2020

Infection with Mycobacterium avium complex in patients without predisposing conditions

1 reference

12 December 2020

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

1 reference

12 December 2020

Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

1 reference

12 December 2020

Medical therapy of Mycobacterium avium-intracellulare pulmonary disease

1 reference

12 December 2020

The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey.

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1 reference

12 December 2020

Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium

1 reference

12 December 2020

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex

1 reference

12 December 2020

Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium

1 reference

12 December 2020

Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach

1 reference

12 December 2020

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

12 December 2020

Macrolides versus azalides: a drug interaction update

1 reference

12 December 2020

Results of operation in Mycobacterium avium-intracellulare lung disease

1 reference

12 December 2020

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

1 reference

12 December 2020

Mycobacterium avium disease: progress at last

1 reference

12 December 2020

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients

1 reference

12 December 2020

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases

1 reference

12 December 2020

Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease

1 reference

12 December 2020

Long-term results of medical treatment in Mycobacterium intracellulare infection

1 reference

12 December 2020

Surgery in the treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

Drug intolerance to high-dose clarithromycin among elderly patients

1 reference

12 December 2020

A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex

1 reference

12 December 2020

10.2165/00002018-199921020-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1001651637

0 references

1 reference